Compare HERZ & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HERZ | GRDX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 33.2M |
| IPO Year | 1995 | 2016 |
| Metric | HERZ | GRDX |
|---|---|---|
| Price | $13.15 | $2.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.7K | ★ 134.0K |
| Earning Date | N/A | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $1.87 |
| 52 Week High | $19.30 | $6.93 |
| Indicator | HERZ | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 29.44 |
| Support Level | N/A | N/A |
| Resistance Level | $16.98 | $2.73 |
| Average True Range (ATR) | 0.32 | 0.83 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 27.69 | 0.00 |
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.